scholarly journals Endothelial Dysfunction through Oxidatively Generated Epigenetic Mark in Respiratory Viral Infections

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 3067
Author(s):  
Spiros Vlahopoulos ◽  
Ke Wang ◽  
Yaoyao Xue ◽  
Xu Zheng ◽  
Istvan Boldogh ◽  
...  
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Clinical Care ◽  
Treatment Options ◽  
Pulmonary Complications ◽  
Epigenetic Mark ◽  
Host Immune System ◽  
Influenza A H1n1 ◽  
Respiratory Viral Infections ◽  
Syncytial Virus

The bronchial vascular endothelial network plays important roles in pulmonary pathology during respiratory viral infections, including respiratory syncytial virus (RSV), influenza A(H1N1) and importantly SARS-Cov-2. All of these infections can be severe and even lethal in patients with underlying risk factors.A major obstacle in disease prevention is the lack of appropriate efficacious vaccine(s) due to continuous changes in the encoding capacity of the viral genome, exuberant responsiveness of the host immune system and lack of effective antiviral drugs. Current management of these severe respiratory viral infections is limited to supportive clinical care. The primary cause of morbidity and mortality is respiratory failure, partially due to endothelial pulmonary complications, including edema. The latter is induced by the loss of alveolar epithelium integrity and by pathological changes in the endothelial vascular network that regulates blood flow, blood fluidity, exchange of fluids, electrolytes, various macromolecules and responses to signals triggered by oxygenation, and controls trafficking of leukocyte immune cells. This overview outlines the latest understanding of the implications of pulmonary vascular endothelium involvement in respiratory distress syndrome secondary to viral infections. In addition, the roles of infection-induced cytokines, growth factors, and epigenetic reprogramming in endothelial permeability, as well as emerging treatment options to decrease disease burden, are discussed.

scholarly journals Concomitant Infections of Influenza A H1N1 and Disseminated Cryptococcosis in an HIV Seropositive Patient

2015 ◽  
Vol 7 (02) ◽  
pp. 134-136 ◽  
Author(s):  
Ankit Gupta ◽  
Malini R Capoor ◽  
Sonal Gupta ◽  
Harish Chand Sachdeva
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
Unusual Case ◽  
Viral Infections ◽  
Dual Infection ◽  
Seropositive Patient ◽  
Seropositive Individual ◽  
Influenza A H1n1 ◽  
Respiratory Viral Infections ◽  
Hiv Seropositive

ABSTRACTRespiratory viral infections, especially influenza have a potential to form a fatal association with cryptococcosis in the setting of compromised immunity. Considering the lethality of these two infections, we report an unusual case of dual infection of pandemic influenza A H1N1 and disseminated cryptococcosis in an HIV seropositive individual.

scholarly journals Role of ILC2 in Viral-Induced Lung Pathogenesis

2021 ◽  
Vol 12 ◽  
Author(s):  
Wendy Fonseca ◽  
Nicholas W. Lukacs ◽  
Srikanth Elesela ◽  
Carrie-Anne Malinczak
Keyword(s):  
Viral Infections ◽  
Treatment Options ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Structural Repair ◽  
Respiratory Viral Infections ◽  
Lung Pathogenesis ◽  
Syncytial Virus

Innate lymphoid type-2 cells (ILC2) are a population of innate cells of lymphoid origin that are known to drive strong Type 2 immunity. ILC2 play a key role in lung homeostasis, repair/remodeling of lung structures following injury, and initiation of inflammation as well as more complex roles during the immune response, including the transition from innate to adaptive immunity. Remarkably, dysregulation of this single population has been linked with chronic lung pathologies, including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrotic diseases (IPF). Furthermore, ILC2 have been shown to increase following early-life respiratory viral infections, such as respiratory syncytial virus (RSV) and rhinovirus (RV), that may lead to long-term alterations of the lung environment. The detrimental roles of increased ILC2 following these infections may include pathogenic chronic inflammation and/or alterations of the structural, repair, and even developmental processes of the lung. Respiratory viral infections in older adults and patients with established chronic pulmonary diseases often lead to exacerbated responses, likely due to previous exposures that leave the lung in a dysregulated functional and structural state. This review will focus on the role of ILC2 during respiratory viral exposures and their effects on the induction and regulation of lung pathogenesis. We aim to provide insight into ILC2-driven mechanisms that may enhance lung-associated diseases throughout life. Understanding these mechanisms will help identify better treatment options to limit not only viral infection severity but also protect against the development and/or exacerbation of other lung pathologies linked to severe respiratory viral infections.

scholarly journals ЕPIDEMIOLOGICAL AND СLINICAL FEATURES OF INFLUENZA IN CHILDREN IN THE STAVROPOL TERRITORY IN THE EPIDEMIC PERIOD OF 2015–2016 AND 2016–2017 YEARS

2019 ◽  
Vol 11 (1) ◽  
pp. 71-75
Author(s):  
S. M. Bezrodnova ◽  
N. A. Yatsenko ◽  
O. O. Kravchenko ◽  
Sh. M. Khurtsilava
Keyword(s):  
Specific Gravity ◽  
Influenza A ◽  
Viral Infections ◽  
Influenza B ◽  
Epidemic Season ◽  
Epidemiological Features ◽  
Influenza A H1n1 ◽  
Epidemic Period ◽  
Microcirculation Disturbance ◽  
Respiratory Viral Infections

Objective: to study the clinical and epidemiological features of influenza in children in the Stavropol Territory.Materials and methods: influenza prevalence is analyzed from 2015 to 2017 the paper used the data from the Territorial Rospotrebnadzor in the Stavropol Territory. We used the following methods: bibliographic, monographic description, epidemiological, analytical, statistical methods.Results: Among the deciphered acute respiratory viral infections, the specific gravity of influenza A (H1N1) 09 in 2016 reached 78%, and in 2017 influenza B prevailed – in 57,4% of children, and influenza A (H3N2) – in 42,6% of cases. In 2016 68,5% of children under 6 years of age, of all admitted, were hospitalized, and in 2017 – 83,86%. We presented the peculiarities of the course of influenza in different epidemic seasons.Conclusion: Unvaccinated children up to 6 years of age have the disease mainly in severe forms and with complications. The epidemic period began to increase in 2015–2016 at week 52, and in 2016–2017 from week 48, ended at week 13 and at week 17. At the epidemic of 2015–2016, intoxication syndrome with chills, microcirculation disturbance, catarrhal syndrome, ARDS prevailed in the clinical picture. The epidemic season of 2016–2017 was characterized by intoxication syndrome, encephalic reaction, hemorrhagic and myalgic syndromes.

scholarly journals “Tiryaq Arba” (a Polyherbal Unani Formulation) as Prophylactic Medicine Against Epidemics of Acute Respiratory Viral Infections

2020 ◽  
Vol 7 (3) ◽  
Author(s):  
Shabnam Ansari ◽  
Ijhar Ahmad ◽  
Mahboob Ali ◽  
Mohd. Maaz
Keyword(s):  
Influenza A Virus ◽  
Influenza A ◽  
Viral Infections ◽  
Antioxidant Properties ◽  
Parainfluenza Virus ◽  
Virus Infections ◽  
Gentiana Lutea ◽  
Respiratory Viral Infections ◽  
Syncytial Virus ◽  
Type 3

: “Tiryaq Arba” is a polyherbal Unani formulation in a majoon dosage form that contains four herbal ingredients, namely habbul ghar (Laurus nobilis), juntiyana romi (Gentiana lutea), murr maki (Commiphora myrrha), and zarawand taweel (Aristolochia longa). The medicine has been used as an antidote against different poisons and as a prophylactic medicine before and/or during epidemics. The constituents have been proposed to act as anti-infective, anti-microbial, and antidote against various infectious agents during epidemics (waba). Scientific experimentation of the above-mentioned constituents has also reinforced their beneficial antiviral, immunomodulatory, and antioxidant properties against epidemics of acute respiratory viral infections such as; severe acute respiratory syndrome coronavirus (SARS-CoV), adenovirus, influenza and influenza A virus, respiratory syncytial virus infections, parainfluenza virus, human rhinovirus B, coxsackievirus, parainfluenza virus type 3, Newcastle disease virus, and influenza A virus, which are a greater cause for morbidity and mortality faced by the world, earlier and at present.

scholarly journals Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1

2011 ◽  
Vol 38 (3) ◽  
pp. 739-742 ◽  
Author(s):  
M. A. Marcos ◽  
S. Ramon ◽  
A. Anton ◽  
E. Martinez ◽  
A. Vilella ◽  
...  
Keyword(s):  
Clinical Relevance ◽  
Influenza A ◽  
Viral Infections ◽  
Influenza A H1n1 ◽  
Respiratory Viral Infections

scholarly journals Narcissus tazetta lectin shows strong inhibitory effects against respiratory syncytial virus, influenza A (H1N1, H3N2, H5N1) and B viruses

2010 ◽  
Vol 35 (1) ◽  
pp. 95-103 ◽  
Author(s):  
Linda S. M. Ooi ◽  
Wing-Shan Ho ◽  
Karry L. K. Ngai ◽  
Li Tian ◽  
Paul K. S. Chan ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Influenza A ◽  
Inhibitory Effects ◽  
Narcissus Tazetta ◽  
Influenza A H1n1 ◽  
Syncytial Virus ◽  
Virus Influenza

Clinical use of Antiviral Drugs

1987 ◽  
Vol 21 (5) ◽  
pp. 399-405 ◽  
Author(s):  
Milap C. Nahata
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Antiviral Agent ◽  
Antiviral Drugs ◽  
Investigational Drug ◽  
Virus Infections ◽  
Herpes Encephalitis ◽  
Herpes Simplex Viruses ◽  
Varicella Zoster ◽  
Syncytial Virus

Remarkable progress has been made in antiviral chemotherapy. Six approved antiviral drugs are now available for the treatment of various viral infections. Trifluridine, idoxuridine and vidarabine are all effective in patients with herpes keratitis; trifluridine is preferred due to its low toxicity. Acyclovir is the drug of choice in patients with infections due to herpes simplex viruses, including genital herpes, herpes encephalitis, and neonatal herpes, and infections due to varicella-zoster virus. Amantadine is the only drug currently available for prophylaxis and treatment of influenza A, but an investigational drug, rimantadine, appears to be equally effective and less toxic than amantadine. Ribavirin is the most recently approved antiviral agent for the treatment of respiratory syncytial virus infections. Numerous antiviral drugs are being studied in patients with acquired immunodeficiency syndrome. Although currently available drugs have improved our ability to manage a variety of viral illnesses, much needs to be learned about specific dosage guidelines based on the studies of pharmacokinetics, pharmacodynamics, potential adverse effects and viral resistance, and the role of combination therapy to optimize therapy.

scholarly journals Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment

2020 ◽  
Vol 92 (3) ◽  
pp. 50-55
Author(s):  
D. A. Lioznov ◽  
E. J. Karnaukhova ◽  
T. G. Zubkova ◽  
E. V. Shakhlanskaya
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Clinical Symptoms ◽  
Randomized Study ◽  
Antiviral Drug ◽  
Main Group ◽  
Average Score ◽  
Control Group ◽  
Symptomatic Therapy ◽  
Respiratory Viral Infections

Aim. To assess the effectiveness of the use of the antiviral drug enisamium iodide in the complex treatment of acute respiratory viral infections (ARVI) caused by various pathogens in routine clinical practice. Materials and methods. А prospective randomized study included 134 patients who were treated in the epidemic season of influenza and ARVI in 20182019. All patients were examined for the presence of influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, coronaviruses, rhinoviruses, adenoviruses in nasopharyngeal swabs by PCR. Patients of the main group received enisamium iodide along with symptomatic therapy, the control group received only symptomatic therapy. The primary parameter of the effectiveness of therapy was evaluated on the scale of the general severity of the manifestations of ARVI (Total Symptom Score TSS) from the 2nd to the 4th day and by the secondary criteria of effectiveness: assessment of the duration of ARVI, the severity of fever, the proportion of patients with normal body temperature, the duration of the main clinical symptoms of acute respiratory viral infections, the proportion of patients in whom complications requiring antibiotics were noted, the dynamics of interferon status on the 6th day. To conduct a statistical analysis, depending on the efficiency parameter, the ANCOVA method with a fixed group factor and an initial score on the TSS severity scale was used as covariates, a criterion for comparing quantitative indicators in two independent groups. Results. According to the results of the analysis of the primary efficacy parameter, the median (interquartile range) of the average score on the scale of the general severity of ARVI manifestations in the main group was 4.33 (3.675.83), in the comparison group 6.00 (4.677.25; p0.001). The duration of systemic and local manifestations of acute respiratory viral infections was statistically significantly less in the main group (p=0.002 and p=0.019, respectively). Prescription of additional therapy was required in 2 (2.9%) patients of the main group (patients taking enisamium iodide), compared with 8 (11.9%) patients in the control group. Serum levels of interferon  and interferon  on the last day of treatment were statistically significantly higher in patients of the main group compared with the control group (p0.001). Treatment (excellent) was evaluated by 42 (62.7%) patients, while in the control group only 17 (25.8%) patients gave similar ratings. Both patients (p0.001) and doctors (p0.002) rated therapy tolerance better in the study group. Conclusion. The results confirmed the safety and effectiveness of enisamium iodide as a treatment for ARVI and influenza. The antiviral, interferonogenic and anti-inflammatory properties of the drug are involved in the formation of an antiviral response and reduce the risk of complications, which makes it possible to reduce the number of symptomatic agents used.

Sign in / Sign up

Export Citation Format

Share Document